EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis

BACKGROUND: Epidermal growth factor receptor (EGFR) mutation testing in tumor tissue is now a common practice in selecting non-small cell lung cancer (NSCLC) patients for EGFR tyrosine kinase inhibitor (TKI) treatment. However, tumor tissues are often absent or insufficient for the testing. Blood is...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Jin-Qiu, Zhang, Yue-Lun, Li, Hai-Tao, Mao, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319537/
https://www.ncbi.nlm.nih.gov/pubmed/28207548
http://dx.doi.org/10.1097/MD.0000000000006151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319537/
https://www.ncbi.nlm.nih.gov/pubmed/28207548
http://dx.doi.org/10.1097/MD.0000000000006151

Ejemplares similares